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Sirtuin 1 (SIRT1) plays an important role in regulating cellular physiological processes, such as metab-
olism, cell degeneration, cell growth, and cell survival. The recent reports showed that microRNAs
(miRNAs) have emerged as the important regulators for cell proliferation, development, cancer forma-
tion, stress responses, cell death, and other physiological conditions in the past decade. More recently,
miRNAs have revealed their prominent role in regulating gene expression and have provided new
aspects of applications in diagnosis, prognosis, and therapeutic strategies in many human diseases. In the
present review, we introduce and discuss the functions of SIRT1 and miRNAs. We also emphasize speciﬁc
aspects of miRNAs that could modulate SIRT1-related signaling transduction and downstream effects,
such as apoptosis, aging, and angiogenesis.
Copyright  2011, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
Open access under CC BY-NC-ND license.LLC.1. Introduction
Protein acetylation is a highly reversible process in mammalian
cell. The function of acetyltransferases is mainly controlled by
directing toward histones; it is equilibrated bymeans of the activity
of the histone deacetylases (HDACs).1 The Class III HDACs are
globally distributed and have been well known to control a variety
of physiopathological conditions, such as inﬂammation, aging,
proliferation, metabolism, differentiation, apoptosis, and cell cycle
regulation as well as stem cell pluripotency.2 Sirtuins (SIRTs),
a family protein having homology with the yeast silent information
regulator 2 protein, are NADþ-dependent HDACs and also directly
maintain the metabolism-related function.3 The proteins of SIRTs
are divided into seven different types, including SIRT1 to SIRT7,4
with a particular physiological process in nucleus, cytoplasm, and
mitochondria.5 A previous study revealed that SIRT1 deacetylates
both histone and nonhistone substrates, indicating that SIRT1 playssearch and Education, Taipei
i Road, Taipei 11217, Taiwan,
u).
linical Gerontology & Geriatrics. Pimportant roles in regulating cellular physiological processes, such
as metabolism, cell degeneration, cell growth, and cell survival.62. SIRT1 regulation by means of posttranslational
modiﬁcation
Reversible posttranslational modiﬁcation of proteins protects
against stress-induced damages. Sumoylation is one of the most
famous posttranslational modiﬁcation and plays the important role
as a molecular switch in the regulation of biological function of
cells. Some transcriptional inhibitors are sumoylated and the
covalent adherence of small ubiquitin-likemodiﬁer-1 to lysine. This
reaction is regulated by a multienzyme process and promotes the
function of transcriptional inhibitors.7 On the other hand, protein
desumoylation is catalyzed by a speciﬁc isopeptidase called
sentrin-speciﬁc protein-1 in extracellular stress.8 Sumoylation and
desumoylation have been considered as mediators in modulating
protein degradation, protein subcellular localization, and protein-
protein interaction as well as enzymatic activity.9 Human SIRT1 is
sumoylated in lysine 734, and sumoylation of lysine 734 manifestly
leads to the enzymatic activity of SIRT1, thereby mitigating
stress-induced apoptosis in cells. Moreover, SIRT1 increases the
association with sentrin-speciﬁc protein-1 under oxidative stressublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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apoptosis.8a
3. SIRT1 is a major regulator of intracellular signaling
transduction
3.1. SIRT1 mediated intracellular signaling transduction by
modulating E2F1 and HIC1
It has been demonstrated that SIRT1 can be regulated at the
posttranscriptional level. The 3’ untranslated (3’ UTR) region of
SIRT1 mRNA can interact with RNA-binding protein hydroxyurea
phosphotransferase (HuR), thereby promoting SIRT1 mRNA
stability and increasing the protein expression level. In oxidative
stress environment, the expression level of HuR-SIRT1 complex is
repressed, which leads to inhibition effects of SIRT1-related activity
and stability. This association between SIRT1 and HuR is critical to
modulate posttranscriptional processing of mRNA transcripts,
which has been manifested as one main mechanism in the regu-
lation of protein abundance.10
Several lines of evidence veriﬁed the stress-mediated intracel-
lular signaling transduction change by modulating SIRT1 protein
expression. Besides, many studies reported that there is a strong
relationship between SIRT1 protein expression and cancer cell
growth.11 E2F transcription factor 1 (E2F1) and hypermethylated in
cancer 1 (HIC1) are two major transcription factors that have been
established to modulate SIRT1 protein expression in oxidative
stress. KIC1 is one kind of cancer repressor with around 80-kDa
molecular weight; it has two binding sites within SIRT1 promoter
and belongs to the bric-a-brac/Pox virus and zinc and Kruppel C2H2
zinc ﬁnger family.12 In normal human tissues, KIC1 is widely
expressed, and it is disconnected with nuclear. KIC1 plays an
important role in negative regulation of SIRT1 expression by
generating a transcriptional suppression complex. This transcrip-
tional suppression complex mitigates SIRT1-mediated p53 repres-
sion bymeans of the N-terminal Pox virus and zinc domain, thereby
attenuating cancer cell growth and tumorigenesis.12b Inhibited
CtBR and HIC1 complex generation is the other way to repress HIC1
activity; a previous study has proved that activating the expression
levels of SIRT1 contributes to attenuate this transcriptional cosup-
pressor formation of CtBR and HIC1.13 On the other hand, E2F1 is
famous for the function of cell cycle regulation, which has one
binding site within SIRT1 promoter, indicating that E2F1 is able to
mediate SIRT1 expression level directly. Under oxidative stress
situation, E2F1 is activated and, as a result, increases SIRT1 function
to mitigate the oxidative injury. Moreover, SIRT1-induced deace-
tylation represses E2F1 function by supplying a negative feedback
loop, which is another important mechanism in controlling cell
survival.11a
3.2. SIRT1 mediates intracellular signaling transduction by
modulating p53
p53 plays a major role in cancer repression; p53 gene is acti-
vated by several types of stress, such as hypoxia, chemotherapeutic
drug, radiation, and oxidative stress.14 In humans, mutates of the
p53 gene expression and p53 pathwayerelated protein expression
are demonstrated to induce cancer growth.15 In normal situation,
p53 is maintained in a balanced ratio between destabilization and
degradation; hence, resting cells contain small amounts of p53.
However, genotoxic stress caused the accumulation of p53, block-
ing this balanced reaction, resulting in cell cycle arrest, aging, and
apoptosis.16 Stress induced p53 acetylation by histone acetyl-
transferases p300/CBP, which has been reported as amajor function
of p53.17 Thus, p53 activation and stress response function can beinhibited by deacetylation of SIRT1.18 Elevated expression level of
SIRT1 leads to excessive deacetylation and repression of p53
expression.12b This mechanism protects against stress-induced
injury in cells; however, it increases cancer risks.
3.3. SIRT1 mediates intracellular signaling transduction by
modulating mitogen-activated protein kinase family
Mitogen-activated protein kinases are a family of Serine/Thre-
onine protein kinases widely preserved in humans and are involved
in many cellular signaling transduction processes, such as cell
proliferation, cell differentiation, cell translocation, and cell death.
However, c-jun N-terminal kinase (JNK)1 and JNK2 are mainly
studied in response to cellular stress.19 A previous study shows that
knockdown of JNK2 expression by small interfering RNAs (siRNA)
leads to a repression of SIRT1 phosphorylation and protein stability,
indicating that JNK2 plays an important role in SIRT1 protein
expression stability and also mediates the phosphorylation of
SIRT1.20
3.4. SIRT1 mediates intracellular signaling transduction by
interacting with poly (adenosine diphosphate-ribose) polymerase 1
Poly (adenosine diphosphate-ribose) polymerase 1 (PARP-1) is
located in the nuclei and participates in chromatin remodeling and
DNA repair. PARP-1 has been reported tomediate several pathways,
such as cell apoptosis and cell death, cell survival and necrosis, cell
autophagy, and adenosine triphosphate depletion.21 Furukawa
et al22 ﬁrst illustrated that oxidative stress induced cell death by
activating PARP-1 and inhibiting SIRT1 expression. In 2009, Ramy
et al revealed that double mutates of PARP-1 and SIRT1 gene
expression cause genome instability and modiﬁcations and repress
lethality in mice.23
3.5. SIRT1 mediates intracellular signaling transduction by
modulating NF-kB
Nuclear factor (NF)-kB has two subunits, including p50 and p65.
SIRT1 can interact with p65 directly and regulates NF-kB tran-
scriptional activity.24 In addition, SIRT1 deacetylates and mitigates
the transcriptional activity of activator protein-1, thereby inhibiting
the proinﬂammatory gene, cyclooxygenase-2, expression.25
Knocking down the SIRT1 expression level promotes NF-kB
activity and proinﬂammatory cytokine secretions.26
3.6. SIRT1 mediates intracellular signaling transduction by means
of its subcellular localization
In general, SIRT1 has been considered to be distributed around
the whole cells.27 Recently, scientists hypothesized that SIRT1
mediates intracellular signaling transduction by means of its
subcellular localization. Tanno et al28 displayed that about 84% of
SIRT1 translocates between cytosol fraction and nuclear fraction
absolutely under oxidative environment. Both heterokaryon shut-
tling assays and the deletion constructs of EGFP-SIRT1 revealed that
cytoplasmic SIRT1 plays a critical role in protecting against oxida-
tive stresseinduced apoptosis.28,29
3.7. SIRT1 mediates intracellular signaling transduction by means
of protein-protein interaction
One important regulatory mechanism for Class I and II HDAC
proteins is regulating the protein function, such as controlling the
protein-protein interaction. Active regulator of SIRT1 (AROS) and
deleted in breast cancer-1 (DBC-1) are two target proteins; they
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transferase-pull down analyses and co-immunoprecipitation
experiments exhibited that AROS protein is associated with the
amino-terminal domain of SIRT1 directly in oxidative condition.
AROS promotes SIRT1 activity, thereby facilitating p53 acetylation
and repressing the expressions of proapoptotic proteins. On the
contrary, DBC-1 and SIRT1 complex has been displayed as a nega-
tive regulator of SIRT1. DBC-1 attenuates the activity of SIRT1 under
oxidative situation.30
4. MicroRNAs
4.1. Introduction of microRNAs
In the past decade, the biological function and biogenesis of
microRNAs (miRNAs) became popular topics for biomedical
researches. MiRNAs, approximately 18e25 nucleotides in length,
are a group of endogenous small and noncoding RNAs. They are
transcribed to form a primary miRNA through RNA polymerase II.
Primary miRNA is processed into precursor miRNA by Drosha and
DRG 8 and is then exported from nucleus to cytoplasm through
exportin 5. The precursor miRNA is modiﬁed by Dicer and the
matured miRNA forms. There are about 1000 different miRNAs that
have been discovered and estimated in human genome.31 MiRNAs
play a critical role in the regulation of gene expression. As expected,
miRNA expression is highly correlated with human diseases, such
as cancer and aging.32 MiRNAs might not only act as oncogenes but
also as tumor suppressors, which further implicates its role as
therapeutic targets.33
4.2. MiRNAs related to aging and cancers
Epigenetics of aging is an emerging ﬁeld involving the mecha-
nisms that affect gene expressions other than inherited DNA
sequences regulating tumorigenesis in multiple cancers. Factors,
such as DNA methylation, histone modiﬁcation, chromatin
remodeling, the polycomb protein groups, and noncoding RNAs,
can all contribute to a broad variety of phenotypes of aging. Among
these, we had focused on a group of miRNAs and their impact on
facets of organismal aging as well as cellular senescence. The
category of small noncoding regulatory RNAs include miRNAs,
siRNAs, PIWI-interacting RNAs, small nucleolar RNAs, and small
nuclear RNAs. Most of the miRNA-mediated regulation occurs at
the posttranslational level, primarily through its near-perfect or
partial complementary ﬁt against the coding region or 3’ UTR of
target mRNA, leading to translational repression and/or degrada-
tion and, therefore, the regulation of gene expression. In rare cases,
they may also promote translation.34
The roles of miRNAs in cancers have been extensively investi-
gated in the past few years. The relevance of miRNAs in cancer was
suggested by the changes in expression patterns35 and recurrent
ampliﬁcation as well as deletion of miRNA genes in cancers. Calin
et al36 were the ﬁrst to report the signature of 13miRNAs capable of
distinguishing between indolent and aggressive chronic lympho-
cytic leukemia. Since then, several miRNAs have emerged as
candidate components of oncogenes and tumor-suppressor
networks.
It has been demonstrated that miRNAs can function both as
oncogenes and tumor suppressors in the development of cancers.
Recently, the connection of miRNA biogenesis and tumor
suppressor networks was elucidated. p53, a well-known tumor
suppressor, regulates diverse physical responses to many cancer-
related stress signals, which could be translated to affect cell
proliferation, cell death, DNA repair, and angiogenesis. Efforts have
beenmade to unravel the linkage betweenp53 and several miRNAs.Xi et al37 found miR-30a-5p, miR-181b, miR-372, let-7g, miR-26a,
let-7b, miR-296, and miR30a-3p were upregulated by wt-p53,
whereas miR-15b, miR-27a, miR200c, miR-191, miR-30c, miR-25,
miR-107, miR-339, miR-125, miR-27b, miR-23a, and miR-10a were
downregulated by wt-p53 in human colon carcinoma cell lines,
suggesting that p53 plays a role in a wide range of miRNA
expression. In another study, the analysis for 470 miRNAs found
12 miRNAs to be signiﬁcantly affected by p53.38 Recent reports
indicated that miRNAs are directly regulated by p53. He et al39
reported that miR-34a, miR-34b, and miR-34c reﬂected p53
status, and the expression of these miRNAs was induced by DNA
damage and oncogenic stress in a p53-dependent manner, leading
to apoptosis or cellular senescence. These ﬁndings elucidated that
miRNAs play crucial roles in the p53 tumor suppressor-related
pathways. Moreover, Yamakuchi et al40a revealed that miR-34a,
a gene that mediates cellular aging and limits longevity, mitigates
SIRT1 expression by modulating p53-related apoptosis and p53
stability and activity. Moreover, Zhao et al40a and Menghini et al40c
displayed that miR-34a and miR-217 induce endothelial progenitor
cell senescence and impede its angiogenesis by suppressing SIRT1.
5. Regulation of SIRT1 by miRNAs
The regulation of SIRT1 expression is available in transcriptional,
posttranscriptional, and posttranslational levels by integrating the
aforementioned. The aim of the present review was to highlight
miRNA as a modulator of SIRT1 expression. We paid attention to
citations that focused on the alteration of miRNA expression in
SIRT1 expression to themain topic. MiR-22 is known to target SIRT1
directly. Xu et al41 reported an effort to identify potential targets for
miR-22 by using softwares miRnada, TargetScan, and Pic Tar. As
a result of the target prediction, miR-22 represses SIRT1 expression
level by binding to 3’ UTR of SIRT1. Next, the authors conﬁrmed the
hypothesis by luciferase reporter assay; the results revealed that
miR-22 inhibits SIRT1 luciferase activity. Moreover, pRB was
dephosphorylated and senescence-associated-b-gel positives were
attenuated by knocking down SIRT1 function. Those results sug-
gested that miR-22 may affect the pRB signaling transduction
pathway of cellular senescenceemodulating SIRT1 function.41
MiR-34a, a famous miRNA of cell cycle regulation, cancer cell
inhibition, and p53-related apoptosis signaling transduction, was
ﬁrst revealed as a posttranscriptional regulator of SIRT1 by means
of miRNAs. MiR-34a binds to SIRT13’ UTR, thereby repressing SIRT1
expression level directly. Overexpression of miR-34a induces
apoptosis and activates acetylation of p53 by mitigating SIRT1
activation in human colon cancer cells. Moreover, knockdown of
miR-34a function by antisense oligonucleotides attenuates the
acetylation of p53 and p53-upregulated modulator of apoptosis
expression in protein level.40a MiR-34a mediates human endothe-
lial cells’ prosenescent responses, increases the fraction of cell G1
phase in cell cycle, and impedes angiogenesis by modulating SIRT1
and forkhead box O transcription factor 1 (FoxO1).40b,42 Farnesoid X
receptor (FXR), a kind of nuclear receptor, plays a major role as
a primary biosensor for endogenous bile acids and regulates the
expression of lipid- and glucose-metabolismerelated genes.43 The
FXR/small heterodimer partner pathway possesses bile acid and
cholesterol levels by suppressing the transcription of cholesterol
cytochrome P450.44 Lee et al45 demonstrated that miR-34a regu-
lates SIRT1 function by mediating FXR/small-small heterodimer
partner pathway in obese mice. Recently, a study showed that
SIRT1 plays a major role in miR-34a-mediated drug resistance. 5-
Fluorouracil (5-FU) is one of the most widely used anticancer
drugs in clinical approach. In colon cancer cells, overexpression of
miR-34a protected against 5-FU-induced cell death; however, the
protective effects were reduced when the SIRT1 expression was
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SIRT1-silenced colon cancer calls. These ﬁndings revealed that miR-
34a promotes drug resistance of 5-FU through downregulation of
SIRT1 function.46
Similar to miR-34a, miR-93 represses SIRT1 expression and
ﬂuorescence intensity in cotransfection assay. The miR-93 expres-
sion level was increased in old rat livers by repressing SIRT1 and
microsomal glutathione S-transferase 1 expression.47 Strum et al48
demonstrated nutritional stress-facilitated proinﬂammatory
responses by the modulation of miR-132-mediated SIRT1 expres-
sion through the NF-kB pathway. Both nutrition deprivation and
overexpression of miR-132 induce interleukin-8 and monocyte
chemoattractant protein 1 expression, suppress SIRT1 expression,
and facilitate acetylation of p65 NF-kB. Moreover, reporter activity
assay displayed thatmiR-132 regulates SIRT1 expression by binding
to 3’ UTR directly.48 MiR-217 is expressed during human endothe-
lial cell senescence, and recently, miR-217 was established as an
inducer of aging and an inhibitor of angiogenesis by mitigating
SIRT1 and FoxO1 activation.40c SIRT1 is an miR-199a-predicted
target gene; Rane et al49 reported miR-199a as a negative regulator
of SIRT1 and hypoxia-inducible factor (HIF)-1a during hypoxia in
cardiac myocytes. miR-200 family is a crucial modulator of EMT,
tumorigenicity, and metastasis. miR-200 family is downregulated
and exhibits tumor-suppressive properties in renal, prostate, breast,
bladder, pancreatic, and gastric cancers. The molecules of miR-200
family are required for the growth of mammary stem cells and
the self-renewal properties of breast cancer stem cells through the
direct targeting of BMI1. Downregulation of miR-200c promotes the
EMT of breast cancer cells, whereas overexpression of miR-200c
induces mesenchymal-epithelial transitions. Notably, miR-200c
regulates the EMT of pancreatic cancer cells and cancer stemness
properties by targeting zinc ﬁnger E-box binding homeobox1/zinc
ﬁnger E-box binding homeobox2, BMI1, and sulﬁte oxidase 2.50
Eades et al51 reported SIRT1 transcript as subject by targeting of
SIRT13’ UTR. The authors also revealed that SIRT1 andmiR-200a are
in a negative feedback regulatory loop. Restoration of miR-200a or
the knockdown of SIRT1 reduced transformation of normal
mammary epithelial cells, evidenced by decreased anchorage-
independent growth and decreased cell migration. In addition,
SIRT1 overexpression is associated with decreased miR-200a in
breast cancer. These ﬁndings provide further evidence for a critical
tumor-suppressive role of SIRT1 and miR-200 family in breast
epithelium.51
MiR-449 has been shown as a tumor repressor. MiR-449 miti-
gates cancer cell proliferation and is downregulated in gastric
cancer. The authors used Affymetrix 133v2 arrays to identify SIRT1
as miR-499 target. The result of luciferase activity assay revealed
SIRT1 as direct target of miR-499. Moreover, they used real-time
polymerase chain reaction and Western blotting assay to conﬁrm
their hypothesis. The SIRT1 expression level was decreased when
miR-499 was overexpressed in gastric cancer cells. These discov-
eries proved that miR-499 mediated cancer cell growth by
involving SIRT1 expression.52 Moreover, several miRNAs, such as
miR-9, miR-181a, miR-181b, miR-204, miR-199b, miR-135, have
been recently demonstrated as a repressor to downregulate SIRT1
level in differentiated mouse tissues. In addition, it has been shown
that SIRT1 expression level is much lower in differentiated mouse
tissue than that in mouse embryonic stem cells.53
6. Conclusion
SIRT1, a NADþ-dependent HDAC, participates a wide range of
biomolecular pathways and interacts with many transcriptional
regulators, including p53, FoxO, NF-kB. SIRT1 is involved in the
regulation of replicative aging, cancer, and metabolism-relatedsignaling transduction. MiRNAs, a small group of noncoding RNAs,
draw more attention than ever and are thought to be a new cate-
gory of tumor suppressor or mediators of signaling transduction. In
this review article, we originated from several mechanisms in the
regulation of SIRT1; moreover, the close links between miRNAs and
SIRT1 are also mentioned. Further studies are needed to under-
stand the interaction regulation mechanism between SirT1 and
miRNAs as well as their targets. Therefore, it will be important to
clarify how the miRNA/SIRT1 regulatory network is controlled in
humans in future research.References
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